• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 2 )*

                

    BRUKER CORPORATION


    (Name of Issuer)

    Common Stock


    (Title of Class of Securities)

    116794108


    (CUSIP Number)

    September 30, 2024


    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [X] Rule 13d-1(b)
    [ ] Rule 13d-1(c)
    [ ] Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.)


    CUSIP No. 116794108

    1. NAMES OF REPORTING PERSONS
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

    Massachusetts Financial Services Company ("MFS")
    04-2747644
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

    (a) [ ]
    (b) [ ]
    Not Applicable
    3. SEC USE ONLY
    4. CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    5. SOLE VOTING POWER 5,366,921
    6. SHARED VOTING POWER 0
    7. SOLE DISPOSITIVE POWER 5,458,374
    8. SHARED DISPOSITIVE POWER 0
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    5,458,374 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    Not Applicable
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    3.6%
    12. TYPE OF REPORTING PERSON

    IA

    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


    Item 1.
    (a) Name of Issuer
    BRUKER CORPORATION
    (b) Address of Issuer's Principal Executive Offices
    40 Manning Road, Billerica, MA 01821
    Item 2.
    (a) Name of Person Filing
    Massachusetts Financial Services Company
    (b) Address of Principal Business Office or, if None, Residence
    111 Huntington Avenue, Boston, MA 02199
    (c) Citizenship
    Delaware
    (d) Title of Class of Securities
    Common Stock
    (e) CUSIP Number
    116794108
    Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:
    (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o).
    (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E);
    (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F);
    (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G);
    (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J).
    Item 4. Ownership.
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
    (a) Amount Beneficially Owned:
    5,458,374 shares of Common Stock consisting of shares beneficially owned by MFS and/or certain other non-reporting entities
    (b) Percent of Class:
    3.6%
    (c) Number of shares as to which such person has:
    (i) sole power to vote or to direct the vote 5,366,921
    (ii) shared power to vote or to direct the vote 0
    (iii) sole power to dispose or to direct the disposition of 5,458,374
    (iv) shared power to dispose or to direct the disposition of 0
    Item 5. Ownership of Five Percent or Less of Class.
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: [ X ]
    Item 6. Ownership of More than Five Percent on Behalf of Another Person.
    Not Applicable
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
    Not Applicable
    Item 8. Identification and Classification of Members of the Group.
    Not Applicable
    Item 9. Notice of Dissolution of Group.

    Not Applicable
    Item 10. Certification.

    By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Massachusetts Financial Services Company
    By: /s/ Lisa Neaves
    Date: November 12, 2024
    Name: Lisa Neaves
    Title: Compliance Officer

    Get the next $BRKR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    12/10/2025$60.00Peer Perform → Outperform
    Wolfe Research
    12/9/2025$40.00Sell
    Goldman
    11/20/2025$60.00Buy
    Rothschild & Co Redburn
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    More analyst ratings

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces $500 Million in Multi-Year Orders from Two Global Healthcare Companies for Supply of High-Performance Superconductors for MRI

    The Bruker Energy & Supercon Technologies (BEST) division, a segment of Bruker Corporation (NASDAQ:BRKR), today announced two multi-year supply agreements for Bruker's latest superconductors, which are used by global radiology companies to build their next generations of magnetic resonance imaging (MRI) magnets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260109007299/en/Typical niobium-titanium-copper composite superconductors suitable for MRI magnets. The combined order value of the two agreements is approximately $500 million in expected future BEST revenues, with different agreement duration periods, with one agreement ex

    1/9/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation to Present at the J.P. Morgan Healthcare Conference

    Bruker Corporation (NASDAQ:BRKR) announced today it will participate in the 45th annual J.P. Morgan Healthcare Conference in San Francisco. Senior leadership will present on behalf of the Company on Monday, January 12th, 2026 at 9:00 AM Pacific Standard Time. A live audio webcast of the presentation will be available on the Investor Relations section of the Company's website at https://ir.bruker.com. A replay of the presentation will be posted in the "Events & Presentations" section of the Bruker Corporation Investor Relations website after the event and will be available for 30 days following the presentation. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Br

    1/7/26 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Phillips Jack

    3 - BRUKER CORP (0001109354) (Issuer)

    1/9/26 6:19:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark exercised 33,843 shares at a strike of $22.19 and sold $1,680,647 worth of shares (33,843 units at $49.66) (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    1/6/26 4:15:20 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Packer Richard A exercised 10,000 shares at a strike of $24.00 and sold $243,230 worth of shares (5,028 units at $48.38), increasing direct ownership by 6% to 89,174 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    12/2/25 4:15:07 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker upgraded by Wolfe Research with a new price target

    Wolfe Research upgraded Bruker from Peer Perform to Outperform and set a new price target of $60.00

    12/10/25 9:02:11 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Goldman initiated coverage on Bruker with a new price target

    Goldman initiated coverage of Bruker with a rating of Sell and set a new price target of $40.00

    12/9/25 8:43:14 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Rothschild & Co Redburn initiated coverage on Bruker with a new price target

    Rothschild & Co Redburn initiated coverage of Bruker with a rating of Buy and set a new price target of $60.00

    11/20/25 8:06:38 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    Bruker Corporation filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    12/9/25 10:10:52 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by Bruker Corporation

    144 - BRUKER CORP (0001109354) (Subject)

    12/1/25 4:14:06 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form SCHEDULE 13G filed by Bruker Corporation

    SCHEDULE 13G - BRUKER CORP (0001109354) (Subject)

    11/14/25 12:53:25 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Consolidates Ownership of TOFWERK in Expansion of Mass Spectrometry Portfolio into New Applied Markets

    TOFWERK is a profitable innovator in compact, ultra-fast time-of-flight (TOF) mass spectrometry for real-time air and semiconductor cleanroom monitoring, food, flavors & fragrances markets, and FIB-TOF accessories for electron microscopes The ultra-sensitive Vocus™ TOF-MS is customizable for real-time air and cleanroom monitoring applications Microwave-induced plasma (MIP)-TOF systems with atto-to-femtogram detection limits for real-time quantification of trace elements and metals Proprietary flow tube-based VUV CI sources for positive and negative trace organics, inorganics and PFAS contaminants Focused Ion Beam (FIB)-TOF accessories for scanning electron microscopes Bruker

    1/8/26 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Quarterly Common Stock Dividend and Preferred Stock Dividend

    Bruker Corporation (NASDAQ:BRKR, BRKRP)) today announced that its Board of Directors ("Board") has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock, par value $0.01 per share (the "Common Stock Dividend"). The Common Stock Dividend will be paid on January 2, 2026 to stockholders of record as of December 8, 2025. The Board also approved payment of a quarterly cash dividend in the amount of $3.6745 per share on the Company's 6.375% Mandatory Convertible Preferred Stock, Series A, par value $0.01 per share (the "Mandatory Convertible Preferred Stock Dividend"). The Mandatory Convertible Preferred Stock Dividend will be paid on Decemb

    11/4/25 4:01:00 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Reports Third Quarter 2025 Financial Results

    Q3 2025 revenues of $860.5 million, down 0.5% year-over-year (yoy), down 4.5% organically Q3 2025 GAAP diluted loss per share $(0.41); non-GAAP diluted earnings per share (EPS) $0.45 Updated FY2025 guidance: Revenue $3.41 to $3.44 billion; reported growth of 1-2% yoy, organic decline of 4-5% Non-GAAP EPS $1.85 to $1.90   Bruker Corporation (NASDAQ:BRKR) today announced financial results for the three and nine months ended September 30, 2025. Frank H. Laukien, Bruker's President and CEO, commented: "In the third quarter, we were encouraged by our mid-single digit percentage organic bookings growth year-over-year, with a Scientific Instruments segment book-to-bill ratio

    11/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials